# US 2023/0056810 A1 · Immuno-optomagnetic point-of-care assay and method for detection of analyte using multi-functional optomagnetic quantum dot nanocrystals (mqds)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056810 A1
- Document ID: US20230056810A1
- Status: Published application
- Kind: A1
- Application number: 17/799,941
- Filed: 2020-02-17
- Published: 2023-02-23
- Earliest claimed: 2020-02-17
- Assignees: Sabanci Universitesi Nanoteknoloji Arastirma Ve Uygulama Merkezi
- Applicants: Sabanci Universitesi Nanoteknoloji Arastirma Ve Uygulama Merkezi
- Inventors: Javed Hussain Niazi KOLKAR MOHAMMED; Anjum QURESHI
- Web page: https://patentgrep.com/patent/US20230056810A1

## CPC

- G01N 33/57515: of the breast
- C09K 11/025: {non-luminescent particle coatings or suspension media}
- C09K 11/883: {with zinc or cadmium}
- G01N 33/54353: {with ligand attached to the carrier via a chemical coupling agent (coatings G01N33/54393)}
- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/588: {with semiconductor nanocrystal label, e.g. quantum dots}
- B82Y 15/00: Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
- B82Y 20/00: Nanooptics, e.g. quantum optics or photonic crystals
- B82Y 25/00: Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
- G01N 2333/91205: Phosphotransferases in general
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C09K: MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

Provided are a novel immuno-optomagnetic point-of-care (PoC) assay and in particular, a method for detecting an analyte using magnetic nanoparticles and quantum dots (QD) having antibodies which are interfaced with the fabricated PoC biochip platform for quantitative analysis, and an immuno-optomagnetic detection method. The method also relates to methods of making such a plurality of conjugated magnetic quantum dot nanoparticles, methods of detecting analytes using such a plurality of conjugated quantum dot nanoparticles.

## Claims

### Claim 1

A method for detecting and quantifying of a target analyte in a test sample, comprising the steps of:
i. providing a point-of-care (PoC) borofloat chip platform containing chambers functionalised with a first analyte specific reagent,
ii. providing multi-colored CdSe/CdS/ZnS core-shell-shell quantum dot (QD) nanocrystals by mixing of pure single colored red and green QD nanocrystals, wherein QD nanocrystals comprise free —COOH functionality,
iii. providing 50-100 nm sized optomagnetic quantum dot (MQD) nanocrystals, wherein 3-10 nm sized CdSe/CdS/ZnS multi-colored QD nanocrystals are coated with 7-12 nm sized magnetic nanoparticles,
iv. providing a plurality of optomagnetic MQD nanocrystals functionalised with a second analyte specific reagent, capable of binding to analyte followed by the first analyte specific reagent,
v. contacting the plurality of optomagnetic MQD nanocrystals with the test sample and forming MQD nanocrystals-second analyte specific reagent-target analyte complex,
vi. separating the MQD nanocrystals-second analyte specific reagent-target analyte complex from test sample using an external magnet,
vii. loading the MQD nanocrystals-second analyte specific reagent-target analyte complex in step vi onto the PoC borofloat chip platform in step i and forming a sandwich complex between the PoC borofloat chip platform and the MQD nanocrystals-second analyte specific reagent-target analyte complex,
viii. exposing a PoC borofloat chip to UV light and detecting and/or quantifying a target analyte fluorescence signal.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the target analyte is protein biomarkers, biomolecule, pathogenic bacteria, virus, nucleic acids (DNA/RNA), environmental contaminant, chemical, pesticide or drug.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the protein biomarker is human-ErbB2/Her2.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the test sample is biological fluids; such as serum, blood, urine, saliva, sweat, CSF or interstitial fluid; water or environmental samples.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the analyte specific reagent is antibody, receptor, DNA/RNA probe, chemical, drug, bacteria or virus.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the first analyte specific reagent is a primary antibody and the second analyte specific reagent is a second antibody.

### Claim 7 (depends on 1)

The method according to claim 1, wherein a UV-excited fluorescence emission signal from the MQD nanocrystals-second analyte specific reagent-target analyte complex is detected directly with a naked eye.

### Claim 8 (depends on 1)

The method according to claim 1, wherein a fluorescence signal from the MQD nanocrystals-second analyte specific reagent-target analyte complex is measured quantitatively using a smartphone camera equipped with an RGB (red, green and blue) profiling algorithm.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the MQD nanocrystals capture target analytes within 15-30 min.

### Claim 10 (depends on 1)

A kit for detecting and quantifying of a target analyte according to claim 1.

### Claim 11 (depends on 10)

The kit according to claim 10, for use in detection of cancer.

### Claim 12 (depends on 11)

The kit according to claim 11, for use in detection of breast cancer.

### Claim 13 (depends on 10)

The kit according to claim 10, wherein the target analyte is human-ErbB2/Her2.

### Claim 14 (depends on 12)

The kit according to claim 12, wherein a detection limit for human ErbB2/Her2 protein is between 620 picograms per mL to 10 nanograms per mL.

### Claim 15 (depends on 10)

The kit according to claim 10, wherein the target analyte is protein biomarkers, biomolecule, pathogenic bacteria, virus, nucleic acids (DNA/RNA), environmental contaminant, chemical, pesticide or drug.

### Claim 16 (depends on 15)

The kit according to claim 15, wherein the protein biomarker is human-ErbB2/Her2.

### Claim 17 (depends on 10)

The kit according to claim 10, wherein the test sample is biological fluids; such as serum, blood, urine, saliva, sweat, CSF or interstitial fluid; water or environmental samples.

### Claim 18 (depends on 10)

The kit according to claim 10, wherein the analyte specific reagent is antibody, receptor, DNA/RNA probe, chemical, drug, bacteria or virus.

### Claim 19 (depends on 10)

The kit according to claim 10, wherein the first analyte specific reagent is a primary antibody and the second analyte specific reagent is a second antibody.

### Claim 20 (depends on 10)

The kit according to claim 10, wherein a UV-excited fluorescence emission signal from the MQD nanocrystals-second analyte specific reagent-target analyte complex is detected directly with a naked eye.
